- Conditions
- Pulmonary Hypertension
- Interventions
- UT-15C SR, Placebo
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 33 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 135
matching trials from the live ClinicalTrials.gov search.
- Conditions
- PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
- Interventions
- Ralinepag
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 48
- States / cities
- Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 38 more
- Conditions
- Neuroblastoma
- Interventions
- Dinutuximab, NK Cells, Lenalidomide
- Drug · Biological
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 11
- States / cities
- Los Angeles, California • San Francisco, California • Atlanta, Georgia + 8 more
- Conditions
- Pulmonary Arterial Hypertension PAH
- Interventions
- Exercise, Standard of Care
- Behavioral
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Breast Cancer
- Interventions
- ChemoFX Assay
- Other
- Lead sponsor
- Precision Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 28
- States / cities
- Long Beach, California • Los Angeles, California • Miami, Florida + 21 more
- Conditions
- Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD)
- Interventions
- Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg
- Drug
- Lead sponsor
- Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut
- Conditions
- Neuroblastoma
- Interventions
- Dinutuximab
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 15 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 11
- States / cities
- Fresno, California • Torrance, California • Orlando, Florida + 8 more
- Conditions
- Interstitial Lung Disease, Pulmonary Hypertension
- Interventions
- Right heart catheterization (RHC)
- Procedure
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 42
- States / cities
- Phoenix, Arizona • Hartford, Connecticut • Lakeland, Florida + 38 more
- Conditions
- PAH
- Interventions
- oral treprostinil
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 9
- States / cities
- Palo Alto, California • San Francisco, California • Aurora, Colorado + 6 more
- Conditions
- Breast Cancer
- Interventions
- Focal Radiation therapy, Pembrolizumab (200mg IV for 30 minutes, CDX-301
- Radiation · Drug · Biological
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 8
- States / cities
- Los Angeles, California • New York, New York • Pittsburgh, Pennsylvania + 2 more
- Conditions
- ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation
- Interventions
- 10 GE Xenokidney
- Biological
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2075
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • New York, New York
- Conditions
- Postoperative Pain, Total Knee Replacement, Total Knee Arthroplasty, Partial Knee Replacement
- Interventions
- SPRINT Peripheral Nerve Stimulation (PNS) System
- Device
- Lead sponsor
- SPR Therapeutics, Inc.
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • San Diego, California • Gainesville, Florida + 7 more
- Conditions
- Ebola Hemorrhagic Fever
- Interventions
- AVI-7537, Normal Saline Solution (NSS)
- Drug · Other
- Lead sponsor
- Sarepta Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Neuroblastoma
- Interventions
- Dinutuximab with Chemotherapy
- Drug
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 4 more
- Conditions
- Respiratory Distress Syndrome, Adult
- Interventions
- Treprostinil Inhalation Solution, Placebo
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- COVID-19, SARS-CoV-2
- Interventions
- Sargramostim, Standard of care
- Drug
- Lead sponsor
- Partner Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 11
- States / cities
- Fullerton, California • Orange, California • San Francisco, California + 8 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- treprostinil diethanolamine
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Advance Solid Tumors, Advanced Malignant Solid Tumors
- Interventions
- a small molecular multi-target kinase inhibitor
- Drug
- Lead sponsor
- ThalassaX Therapeutics United States Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Sarasota, Florida • Boston, Massachusetts + 1 more
- Conditions
- Healthy
- Interventions
- UT-15C, ethanol
- Drug · Other
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Covid19, SARS-CoV Infection
- Interventions
- Sargramostim, Placebo
- Drug
- Lead sponsor
- Partner Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Canoga Park, California + 30 more
- Conditions
- Systemic Sclerosis
- Interventions
- treprostinil diethanolamine
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Ann Arbor, Michigan
- Conditions
- Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
- Interventions
- Inhaled treprostinil solution, Placebo solution
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 188 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more
- Conditions
- Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Serous Adenocarcinoma
- Interventions
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration
- Biological · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Buffalo, New York • Houston, Texas